Next Generation Antibody Therapies Market – Technological breakthroughs, Value chain and stakeholder analysis by 2025

Antibodies are potent biopharmaceutical agents designed to target specific cells. Many researchers have concentrated their efforts to develop antibodies specific to the antigens present on cancer cells. Research and development in the field of antibodies is progressing rapidly. In the past 25 years, over 30 immunoglobulins (IgGs) and their derivatives have been approved for various indications. The currently approved antibody drugs are used not only to treat diseases that affect large number of patients (such as inflammatory diseases and cancer), but also for indications that require special regulatory procedures.

Antibody production has attracted researchers across the world owing to several advantages such as wider therapeutic window, high efficacy to treat certain diseases, and easy development process. Due to these advantages, the global next generation antibody therapies market is experiencing impressive growth. Research and development is also being carried out to create antibody fragments that only bind and neutralize the target, but do not provoke any immune response in contrast to the full length antibody. Moreover, high number of studies are performed in the area of bispecific antibodies that bind to two different targets.

The global next generation antibody therapies market can be segmented based on type of antibody, application, end-user, and region. In terms of type of antibody, the market can be categorized into antibody-drug conjugates (ADCs), bispecific antibodies, intrabodies, alternative protein scaffold, antibody fragments and single domain antibodies, antibody with modified Fc functions (engineered antibodies), and others. Based on application, the global next generation antibody therapies market can be divided into oncology, autoimmune diseases, and others. In terms of region, the market can be segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

The global next generation antibody therapies market is expected to register double digit growth rate owing to increasing efforts by the pharmaceutical and biotechnology companies and research laboratories to develop new antibodies that can treat major diseases such as cancer, rheumatoid arthritis, and other chronic diseases. Additionally, large number of antibody drug conjugates under clinical study is likely to boost market growth in the near future. However, small number of commercially available antibody drug conjugates and high cost limit the uptake of these drugs. This in turn restrains the market. Moreover, stringent government regulations such as those imposed by the U.S. FDA and high cost of production of antibodies are anticipated to hamper the growth of the global next generation antibody therapies market.

North America dominates the global next generation antibody therapies market. Growth of the market in North America is attributed to increasing research and development on antibodies by pharmaceutical and biotechnology companies. Europe is considered to be the second largest market for next generation antibody therapies owing to the strong presence of biotechnology and pharmaceutical companies in the region. Countries in Asia Pacific such as India and China are the emerging markets for next generation antibody production due to rising prevalence of cancer and other chronic diseases, and large population base for conducting clinical trials. Additionally, large number of R&D activities in the region and cost efficient research services contribute to the growth of the market in Asia Pacific.

Request a Brochure to stay abreast on the key trends impacting this market @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=32147

Major players competing in the global next generation antibody therapies market are Amgen, Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Bayer AG, F. Hoffmann-La Roche Ltd., Genmab A/S, Kyowa Hakko Kirin Co. Ltd., ImmunoGen, Inc., Pfizer, Inc., Seattle Genetics, Inc. and Xencor, Inc.